Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis
about
Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewMethotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trialsTreatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexateThe effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.Preventing Heart Failure in Inflammatory and Immune DisordersImmune activation and cardiovascular disease in chronic HIV infection.MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic DrugsImportant issues at heart: cardiovascular risk management in rheumatoid arthritis.Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis.Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritisEfficacy of baricitinib in the treatment of rheumatoid arthritis.Response to: Immortal Time Bias: Comment on the Article by Gwinnutt et al.Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis.Associations between asymmetric dimethylarginine, homocysteine, and the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism (rs1801133) in rheumatoid arthritis.Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry.Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approachRisk of liver disease in methotrexate treated patients.Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence.Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials.Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice.Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritisRepurposing existing drugs for cardiovascular risk management: a focus on methotrexate
P2860
Q26995202-D0439E48-ADB3-4889-AE48-CACB55479123Q28085725-01ACB2F9-3622-49E8-A8D7-2314C142C2B0Q35120688-B658AEC9-F747-4053-838D-9EC11589558FQ35135831-1E33B875-8C9A-40D7-8453-E2B2FC290AF5Q35994802-86A73026-3B16-43DD-9B85-4FF20EE622C3Q36556082-8AA01E7B-B650-4A2F-BF32-4276776C9915Q36625596-64DFBBEF-E26D-452C-A12C-9E3DB60D8825Q36734580-B9649DD5-B980-43B5-9993-548C58BE984DQ37058794-62DDD25B-3C12-48A7-BC6E-AA9B4CAF9299Q37745676-ACAE0EB7-9F86-446E-9A3D-B1FCD6ED80FCQ38191199-E22971D9-4286-4839-8C87-7542484E3238Q38191519-74C8F7C4-FBC3-4F50-A2AE-4FE93B87B797Q38652849-A92CE4A1-E7D3-4C4B-90ED-378BCDF9AC90Q40053440-71DF90A0-12BF-4648-B76D-C53F1A8C97D1Q40298171-9E925255-5BE2-4BF3-9FF7-A447998D3193Q40474665-F8C15B27-6F94-48E6-88D2-DB02209BC743Q40813488-C8A0BD08-B34B-439D-8DA9-55F7F3610CB2Q41102153-59D9C553-1A71-485C-BF3B-44A8E1D8D401Q41514844-3F8725C7-14B3-4671-B412-8CCFB38F76D1Q41581523-EC4A6CB9-13EF-4C92-B881-395FCD853D8BQ42363647-3EC3A11D-107C-4D9E-8108-725A49EC40A9Q50074049-3BA074C6-4D7E-4C76-850B-B9F7F59DCD1FQ51728375-616B0280-AF1C-4D2B-B63F-81FBEFE6179EQ52940652-184BC9A3-400E-49CE-B914-CF19441BAEC8Q55044448-743CF8FD-7DC8-4374-927A-BF687D67AEC3Q57330054-50FFB65A-A5D8-4943-927B-4BA1E721BF34Q59135667-73C1606F-E3F5-46C4-9D72-379F985B6C2A
P2860
Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@ast
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@en
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@nl
type
label
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@ast
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@en
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@nl
prefLabel
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@ast
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@en
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@nl
P2093
P2860
P356
P1476
Propensity-adjusted associatio ...... rvival in rheumatoid arthritis
@en
P2093
Abhijit Dasgupta
Helen Hubert
James F Fries
Mary Chester M Wasko
Michael M Ward
P2860
P304
P356
10.1002/ART.37723
P407
P577
2013-02-01T00:00:00Z